1 week Ago By Defense World Staff
Nutriband Inc. ( NASDAQ:NTRB – Free Report ) – Analysts at Noble Financial issued their FY2025 earnings estimates for shares of Nutriband in a research report issued to clients and investors on Wednesday, January 22nd. Noble Financial analyst R.
Leboyer expects that the company will post earnings per share of ($0.60) for the year. Noble Financial has a “Outperform” rating and a $13.
00 price objective on the stock. Noble Financial also issued estimates for Nutriband’s Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.
13) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.
08) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at $1.45 EPS and FY2028 earnings at $3.
66 EPS. Nutriband ( NASDAQ:NTRB – Get Free Report ) last announced its quarterly earnings data on Tuesday, December 3rd. The company reported ($0.
12) EPS for the quarter. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.
49%. Nutriband Price Performance Nutriband Company Profile ( Get Free Report ) Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Featured Stories Five stocks we like better than Nutriband Industrial Products Stocks Investing Bloom Energy: Powering the Future With Decentralized Energy What Investors Need to Know About Upcoming IPOs Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul 3 Warren Buffett Stocks to Buy Now Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter ..
